Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies
1 hsa-let-7b-5p ABL1 0.6 0.0014 -1.32 0 miRNAWalker2 validate -0.23 0 NA
2 hsa-miR-149-5p ABL1 2.94 0 -1.32 0 miRNAWalker2 validate -0.14 0 NA
3 hsa-miR-484 ABL1 1.82 0 -1.32 0 miRNAWalker2 validate -0.28 0 NA
4 hsa-miR-148a-3p ACVR1 1.27 0 -0.44 0.01143 miRNAWalker2 validate; miRTarBase -0.11 0.00035 NA
5 hsa-miR-148a-3p ADARB1 1.27 0 -1.93 0 miRNAWalker2 validate -0.31 0 NA
6 hsa-miR-148a-3p APC 1.27 0 -0.6 0.00012 miRNAWalker2 validate -0.12 2.0E-5 NA
7 hsa-miR-181a-5p ATM 2.3 0 -0.69 1.0E-5 miRNAWalker2 validate; miRTarBase -0.13 3.0E-5 24531888; 27150990; 21102523; 26113450; 23656790 Ataxia-telangiectasia mutation ATM was predicted as a target gene of miR-181a with bioinformatics analysis and was verified by lucifersae reporter assay; A luciferase reporter assay demonstrated that ATM was a direct target of miR-181a miR-181a mimics transfection down regulated ATM mRNA and protein expression; There was inverse correlation between miR-181a and ATM protein expression in gastric cancer and normal gastric tissues; Our study demonstrates that over-expression of miR-181a might be involved in development of gastric cancer by promoting proliferation and inhibiting apoptosis probably through directly targeting ATM miR-181a modulation may be a potential strategy for the development of miRNA-based therapy of gastric cancer;MiR 181a Promotes Proliferation of Human Acute Myeloid Leukemia Cells by Targeting ATM; Dual luciferase reporter gene assay showed that miR-181a significantly suppressed the reporter gene activity containing ATM 3'-UTR by about 56.8% P < 0.05 but it didn't suppress the reporter gene activity containing 3'-UTR ATM mutation; Western blot showed that miR-181a significantly downregulated the expression of ATM in human leukemia cells; It is also found that miR-181a was significantly increased in AML which showed a negative correlation with ATM expression; miR-181a promotes cell proliferation in AML by regulating the tumor suppressor ATM thus it plays the role as oncogene in pathogenesis of AML;Ataxia telangiectasia mutated ATM a target gene of miR-181 exhibited reduced expression in mammospheres and upon TGF-β treatment;miR 181a promotes G1/S transition and cell proliferation in pediatric acute myeloid leukemia by targeting ATM; Pediatric AML patients and healthy controls were enrolled and the expression of miR-181a and ataxia telangiectasia mutated ATM in tissues were examined using quantitative PCR; Moreover cell proliferation and cell cycle were evaluated in several cell lines HL60 NB4 and K562 by using flow cytometry after transfected with miR-181a mimics and inhibitors or ATM siRNA and control siRNA; Finally ATM as the potential target protein of miR-181a was examined; We found that miR-181a was significantly increased in pediatric AML which showed an inverse association with ATM expression; Luciferase activity of the reporter construct identified ATM as the direct molecular target of miR-181a; The results revealed novel mechanism through which miR-181a regulates G1/S transition and cell proliferation in pediatric AML by regulating the tumor suppressor ATM providing insights into the molecular mechanism in pediatric AML;We report that miR-181a and miR-181b were overexpressed in more aggressive breast cancers and their expression correlates inversely with ATM levels
8 hsa-miR-18a-5p ATM 3.79 0 -0.69 1.0E-5 miRNAWalker2 validate; miRTarBase -0.13 0 23437304; 25963391; 23857602; 23229340 MicroRNA 18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer; Through in silico search the 3'UTR of Ataxia telangiectasia mutated ATM contains a conserved miR-18a binding site; Expression of ATM was down-regulated in CRC tumors p<0.0001 and inversely correlated with miR-18a expression r = -0.4562 p<0.01; This was further confirmed by the down-regulation of ATM protein by miR-18a; As ATM is a key enzyme in DNA damage repair we evaluated the effect of miR-18a on DNA double-strand breaks; miR-18a attenuates cellular repair of DNA double-strand breaks by directly suppressing ATM a key enzyme in DNA damage repair;However the upregulation of miR-18a suppressed the level of ataxia-telangiectasia mutated and attenuated DNA double-strand break repair after irradiation which re-sensitized the cervical cancer cells to radiotherapy by promoting apoptosis;Furthermore we used antisense oligonucleotides against micro RNAs miRNA or miRNA overexpression plasmids to study the role of miR-18a and -106a on ATM expression; Furthermore we identified that ERα activates miR-18a and -106a to downregulate ATM expression; We reveal a novel mechanism involving ERα and miR-18a and -106a regulation of ATM in breast cancer;MicroRNA 18a upregulates autophagy and ataxia telangiectasia mutated gene expression in HCT116 colon cancer cells; Previous studies showed that certain microRNAs including miR-18a potentially regulate ATM in cancer cells; However the mechanisms behind the modulation of ATM by miR-18a remain to be elucidated in colon cancer cells; In the present study we explored the impact of miR-18a on the autophagy process and ATM expression in HCT116 colon cancer cells; Western blotting and luciferase assays were implemented to explore the impact of miR-18a on ATM gene expression in HCT116 cells; Moreover miR-18a overexpression led to the upregulation of ATM expression and suppression of mTORC1 activity; Results of the present study pertaining to the role of miR-18a in regulating autophagy and ATM gene expression in colon cancer cells revealed a novel function for miR-18a in a critical cellular event and on a crucial gene with significant impacts in cancer development progression treatment and in other diseases
9 hsa-miR-19b-3p ATM 2.5 0 -0.69 1.0E-5 miRNAWalker2 validate -0.17 0 NA
10 hsa-miR-92a-3p ATM 2.06 0 -0.69 1.0E-5 miRNAWalker2 validate -0.17 0 NA
11 hsa-miR-148a-3p BTBD3 1.27 0 -0.6 0.00457 miRNAWalker2 validate -0.12 0.00126 NA
12 hsa-miR-335-5p CCNA1 1.77 0 -0.8 0.29528 miRNAWalker2 validate -0.25 0.00952 NA
13 hsa-miR-23b-3p CCNB2 -0.25 0.1502 3.44 0 miRNAWalker2 validate -0.35 8.0E-5 NA
14 hsa-miR-106b-5p CCND1 2.47 0 0.08 0.84033 miRNAWalker2 validate; miRTarBase -0.19 0.01301 NA
15 hsa-miR-15b-5p CCND1 1.57 0 0.08 0.84033 miRNAWalker2 validate; miRTarBase -0.27 0.0019 NA
16 hsa-miR-195-5p CCND1 -1.45 0 0.08 0.84033 miRNAWalker2 validate; miRTarBase -0.23 0.00278 21350001; 26631043; 25823925 Raf-1 and Ccnd1 were identified as novel direct targets of miR-195 and miR-497 miR-195/497 expression levels in clinical specimens were found to be correlated inversely with malignancy of breast cancer;MiR 195 inhibits the proliferation of human cervical cancer cells by directly targeting cyclin D1; The present study was to evaluate the level of miR-195 and cyclin D1 in CC tissues and cells; We further investigated the molecular mechanisms of miR-195 and cyclin D1 in CC cell lines HeLa and SiHa; Furthermore the expression of miR-195 was inversely proportional to that of cyclin D1 mRNA or protein p = 0.013 p = 0.015 respectively; However the inhibitor of miR-195 promoted the expression of cyclin D1 and cell proliferation; In conclusion our data suggest that miR-195 may have the potential role in treatment of CC patients as well as miR-195 is a novel regulator of invasiveness and tumorigenicity in CC cells by targeting cyclin D1;MicroRNA profiling identifies MiR 195 suppresses osteosarcoma cell metastasis by targeting CCND1; Meanwhile CCND1 was identified as the target gene of miR-195 and further studied; More importantly using real-time PCR we evaluated the expression of miR-195 and CCND1 in osteosarcoma samples from 107 frozen biopsy tissues and 99 formalin- or paraformalin-fixed paraffin-embedded FFPE tissues; Results indicated lowly expressed miR-195 or highly CCND1 correlated with positive overall survival and their expression inversely related to each other; In summary our study suggests miR-195 functions as a tumor metastasis suppressor gene by down-regulating CCND1 and can be used as a potential target in the treatment of osteosarcoma
17 hsa-miR-19a-3p CCND1 3.42 0 0.08 0.84033 miRNAWalker2 validate; miRTarBase -0.13 0.03027 25985117 Moreover miR-19a might play inhibitory roles in HCC malignancy via regulating Cyclin D1 expression
18 hsa-miR-19b-1-5p CCND1 2.58 0 0.08 0.84033 miRNAWalker2 validate; miRTarBase -0.15 0.02853 NA
19 hsa-miR-338-3p CCND1 0.45 0.14458 0.08 0.84033 miRNAWalker2 validate; miRTarBase -0.15 0.02359 NA
20 hsa-miR-365a-3p CCND1 -0.04 0.85911 0.08 0.84033 miRNAWalker2 validate; miRTarBase -0.21 0.02249 NA
21 hsa-miR-374b-5p CCND1 0.07 0.72267 0.08 0.84033 miRNAWalker2 validate -0.42 0.00013 NA
22 hsa-miR-92a-3p CCND1 2.06 0 0.08 0.84033 miRNAWalker2 validate -0.19 0.02573 NA
23 hsa-let-7a-5p CCND2 0.62 3.0E-5 -2.43 0 miRNAWalker2 validate; miRTarBase; TargetScan -0.5 0.0001 20418948 MicroRNA let 7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2
24 hsa-let-7b-5p CCND2 0.6 0.0014 -2.43 0 miRNAWalker2 validate; miRTarBase -0.37 0.0002 NA
25 hsa-miR-106b-5p CCND2 2.47 0 -2.43 0 miRNAWalker2 validate; miRTarBase -0.72 0 NA
26 hsa-miR-141-3p CCND2 5.02 0 -2.43 0 TargetScan -0.34 0 NA
27 hsa-miR-15a-5p CCND2 2.35 0 -2.43 0 miRNAWalker2 validate; miRTarBase -0.56 0 NA
28 hsa-miR-16-5p CCND2 1.76 0 -2.43 0 miRNAWalker2 validate -0.62 0 NA
29 hsa-miR-17-5p CCND2 3.27 0 -2.43 0 miRNAWalker2 validate; miRTarBase; TargetScan -0.58 0 NA
30 hsa-miR-182-5p CCND2 3.54 0 -2.43 0 miRNAWalker2 validate; miRTarBase -0.42 0 NA
31 hsa-miR-19b-3p CCND2 2.5 0 -2.43 0 miRNAWalker2 validate -0.64 0 NA
32 hsa-miR-20a-5p CCND2 3.16 0 -2.43 0 miRNAWalker2 validate; miRTarBase -0.55 0 NA
33 hsa-miR-301a-3p CCND2 2.81 0 -2.43 0 miRNAWalker2 validate -0.49 0 NA
34 hsa-miR-320a CCND2 0.44 0.03902 -2.43 0 miRNAWalker2 validate -0.37 4.0E-5 NA
35 hsa-miR-324-3p CCND2 2.09 0 -2.43 0 miRNAWalker2 validate -0.57 0 NA
36 hsa-miR-335-5p CCND2 1.77 0 -2.43 0 miRNAWalker2 validate -0.2 8.0E-5 NA
37 hsa-miR-378a-3p CCND2 -0.11 0.71619 -2.43 0 miRNAWalker2 validate -0.26 2.0E-5 NA
38 hsa-miR-423-5p CCND2 0.96 0 -2.43 0 miRNAWalker2 validate -0.68 0 NA
39 hsa-miR-877-5p CCND2 2.95 0 -2.43 0 miRNAWalker2 validate -0.36 0 NA
40 hsa-miR-96-5p CCND2 4.89 0 -2.43 0 TargetScan -0.38 0 NA
41 hsa-miR-27b-3p CCND3 0.2 0.29563 0.14 0.39731 miRNAWalker2 validate -0.13 0.00231 NA
42 hsa-miR-23b-3p CDC20 -0.25 0.1502 3.89 0 miRNAWalker2 validate -0.44 1.0E-5 NA
43 hsa-miR-30a-5p CDC20 -0.88 0.00051 3.89 0 miRNAWalker2 validate -0.14 0.03688 NA
44 hsa-let-7a-5p CDC25B 0.62 3.0E-5 0.78 0.00479 miRNAWalker2 validate -0.2 0.02874 NA
45 hsa-miR-141-3p CDC25B 5.02 0 0.78 0.00479 TargetScan -0.12 0 NA
46 hsa-miR-23b-3p CDK2 -0.25 0.1502 0.94 0 miRNAWalker2 validate -0.11 0.0284 NA
47 hsa-miR-103a-3p CDK6 1.44 0 -0.77 0.06479 miRNAWalker2 validate -0.74 0 NA
48 hsa-miR-107 CDK6 1.31 0 -0.77 0.06479 miRNAWalker2 validate; miRTarBase -0.54 0 19407485; 22491216; 21264532; 19688090 Enforced expression of miR-107 in MiaPACA-2 and PANC-1 cells downregulated in vitro growth and this was associated with repression of the putative miR-107 target cyclin-dependent kinase 6 thereby providing a functional basis for the epigenetic inactivation of this miRNA in pancreatic cancer;Levels of known miR-107 targets protein kinase Cε PKCε cyclin-dependent kinase 6 CDK6 and hypoxia-inducible factor 1-β HIF1-β decreased following NP/pre-miR-107 treatment;We have identified miR-107 as a potential regulator of CDK6 expression; A bioinformatics search revealed a putative target site for miR-107 within the CDK6 3' untranslated region; Expression of miR-107 in gastric cancer cell lines was found inversely correlated with CDK6 expression; miR-107 could significantly suppress CDK6 3' UTR luciferase reporter activity and this effect was not detectable when the putative 3' UTR target site was mutated; Consistent with the results of the reporter assay ectopic expression of miR-107 reduced both mRNA and protein expression levels of CDK6 inhibited proliferation induced G1 cell cycle arrest and blocked invasion of the gastric cancer cells; Our results suggest that miR-107 may have a tumor suppressor function by directly targeting CDK6 to inhibit the proliferation and invasion activities of gastric cancer cells;Using miRNA-target prediction analyses and the array data we listed up a set of likely targets of miR-107 and miR-185 for G1 cell cycle arrest and validate a subset of them using real-time RT-PCR and immunoblotting for CDK6
49 hsa-miR-141-3p CDK6 5.02 0 -0.77 0.06479 TargetScan -0.28 0 NA
50 hsa-miR-16-5p CDK6 1.76 0 -0.77 0.06479 miRNAWalker2 validate; miRTarBase -0.21 0.02241 NA
51 hsa-miR-17-5p CDK6 3.27 0 -0.77 0.06479 TargetScan -0.17 0.00702 NA
52 hsa-miR-185-5p CDK6 2.34 0 -0.77 0.06479 miRNAWalker2 validate -0.42 0 19688090 Using miRNA-target prediction analyses and the array data we listed up a set of likely targets of miR-107 and miR-185 for G1 cell cycle arrest and validate a subset of them using real-time RT-PCR and immunoblotting for CDK6
53 hsa-miR-191-5p CDK6 2.3 0 -0.77 0.06479 miRNAWalker2 validate; miRTarBase -0.71 0 NA
54 hsa-miR-218-5p CDK6 -0.57 0.0552 -0.77 0.06479 miRNAWalker2 validate -0.15 0.02404 23996750 Ectopic expression of miR-218 in HepG2 cells resulted in suppressed cell proliferation and enhanced cell apoptosis as well as the down-regulation of Bmi-1 and CDK6 mRNA and protein expressions P<0.05; The low-expression of miR-218 is correlated with malignant clinicopathological characteristics of HCC and miR-218 may inhibit cell proliferation and promote cell apoptosis by down-regulating Bmi-1 and CDK6 in HCC
55 hsa-miR-29b-3p CDK6 1.66 0 -0.77 0.06479 miRNAWalker2 validate; miRTarBase -0.22 0.00223 23245396; 25472644; 26180082; 23591808; 27230400; 20086245 The IFN-γ-induced G1-arrest of melanoma cells involves down-regulation of CDK6 which we proved to be a direct target of miR-29 in these cells;Moreover miR-29b inhibited the expression of MCL1 and CDK6;Knockdown of NTSR1 increased the expression of miR-29b-1 and miR-129-3p which were responsible for the decreased CDK6 expression;Here we have identified the oncogene cyclin-dependent protein kinase 6 CDK6 as a direct target of miR-29b in lung cancer;MiR 29b suppresses the proliferation and migration of osteosarcoma cells by targeting CDK6; In this study we investigated the role of miR-29b as a novel regulator of CDK6 using bioinformatics methods; We demonstrated that CDK6 can be downregulated by miR-29b via binding to the 3'-UTR region in osteosarcoma cells; Furthermore we identified an inverse correlation between miR-29b and CDK6 protein levels in osteosarcoma tissues; The results revealed that miR-29b acts as a tumor suppressor of osteosarcoma by targeting CDK6 in the proliferation and migration processes;microRNA expression profile and identification of miR 29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma; Furthermore we demonstrate miR-29 inhibition of CDK6 protein and mRNA levels by direct binding to 3'-untranslated region; Inverse correlation between miR-29 and CDK6 was observed in MCL
56 hsa-miR-29c-3p CDK6 -0.01 0.971 -0.77 0.06479 miRNAWalker2 validate; miRTarBase -0.58 0 26396669 Furthermore through qPCR and Western blot assays confirmed that overexpression of miR-29c reduced CDK6 mRNA and protein levels; miR-29c could inhibit the proliferation migration and invasion of bladder cancer cells via regulating CDK6
57 hsa-miR-34a-5p CDK6 1.9 0 -0.77 0.06479 miRNAWalker2 validate; miRTarBase -0.52 0 21702042; 26104764 Molecular analyses identified Cdk6 and sirtuin SIRT-1 as being targeted by miR-34a in MI-TCC cells however inhibition of Cdk6 and SIRT-1 was not as effective as pre-miR-34a in mediating chemosensitization;The expression of microRNA 34a is inversely correlated with c MET and CDK6 and has a prognostic significance in lung adenocarcinoma patients; We found significant inverse correlations between miR-34a and c-MET R = -0.316 P = 0.028 and CDK6 expression R = -0.4582 P = 0.004
58 hsa-miR-501-3p CDK6 1.83 0 -0.77 0.06479 TargetScan -0.41 0 NA
59 hsa-let-7f-5p CDKN1A 0.5 0.00356 -1.29 0 miRNAWalker2 validate -0.24 0.00297 NA
60 hsa-miR-106a-5p CDKN1A 2.49 0 -1.29 0 miRNAWalker2 validate; miRTarBase -0.13 0.00055 25510666 After prediction with online software we further used dual-luciferase reporter gene assay to ensure that TP53INP1 and CDKN1A might be the direct targets of miR-106a
61 hsa-miR-106b-5p CDKN1A 2.47 0 -1.29 0 miRNAWalker2 validate; miRTarBase -0.3 0 NA
62 hsa-miR-17-5p CDKN1A 3.27 0 -1.29 0 miRNAWalker2 validate; miRTarBase; TargetScan -0.17 3.0E-5 26482648; 24989082 The low expressions of miR-17 and miR-92 families can maintain cisplatin resistance through the regulation of CDKN1A and RAD21;According to PicTar and Miranda algorithms which predicted CDKN1A p21 as a putative target of miR-17 a luciferase assay was performed and revealed that miR-17 directly targets the 3'-UTR of p21 mRNA
63 hsa-miR-182-5p CDKN1A 3.54 0 -1.29 0 miRNAWalker2 validate -0.11 0.00142 NA
64 hsa-miR-20a-5p CDKN1A 3.16 0 -1.29 0 miRNAWalker2 validate; miRTarBase -0.17 7.0E-5 26012475 Using the poorly tumorigenic and TGF-β-sensitive FET cell line that expresses low miR-20a levels we first confirmed that miR-20a downmodulated CDKN1A expression both at mRNA and protein level through direct binding to its 3'-UTR; Moreover besides modulating CDKN1A miR-20a blocked TGF-β-induced transactivation of its promoter without affecting the post-receptor activation of Smad3/4 effectors directly; Finally miR-20a abrogated the TGF-β-mediated c-Myc repression a direct inhibitor of the CDKN1A promoter activation most likely by reducing the expression of specific MYC-regulating genes from the Smad/E2F-based core repressor complex
65 hsa-miR-20b-5p CDKN1A 2.08 1.0E-5 -1.29 0 miRNAWalker2 validate; miRTarBase -0.11 7.0E-5 NA
66 hsa-miR-28-5p CDKN1A 0.23 0.07429 -1.29 0 miRNAWalker2 validate; miRTarBase -0.56 0 NA
67 hsa-miR-335-5p CDKN1A 1.77 0 -1.29 0 miRNAWalker2 validate -0.15 2.0E-5 NA
68 hsa-miR-345-5p CDKN1A 3.64 0 -1.29 0 miRNAWalker2 validate; miRTarBase -0.21 0 NA
69 hsa-miR-363-3p CDKN1A 1.51 0.00021 -1.29 0 miRNAWalker2 validate; miRTarBase -0.12 0.00029 NA
70 hsa-miR-423-3p CDKN1A 2.58 0 -1.29 0 miRNAWalker2 validate; miRTarBase -0.2 6.0E-5 NA
71 hsa-miR-503-5p CDKN1A 3.67 0 -1.29 0 miRNAWalker2 validate; miRTarBase -0.11 0.00188 NA
72 hsa-miR-505-5p CDKN1A 1.89 0 -1.29 0 miRNAWalker2 validate -0.2 3.0E-5 NA
73 hsa-miR-93-5p CDKN1A 3.04 0 -1.29 0 miRNAWalker2 validate; miRTarBase -0.23 0 25633810 MicroRNA 93 activates c Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A; We confirmed that miR-93 directly bound with the 3' untranslated regions of the tumor-suppressor genes PTEN and CDKN1A respectivelyand inhibited their expression; We concluded that miR-93 stimulated cell proliferation migration and invasion through the oncogenic c-Met/PI3K/Akt pathway and also inhibited apoptosis by directly inhibiting PTEN and CDKN1A expression in human HCC
74 hsa-miR-942-5p CDKN1A 2.35 0 -1.29 0 miRNAWalker2 validate -0.26 0 NA
75 hsa-miR-96-5p CDKN1A 4.89 0 -1.29 0 miRNAWalker2 validate; miRTarBase -0.13 2.0E-5 26582573 Upregulation of microRNA 96 and its oncogenic functions by targeting CDKN1A in bladder cancer; Bioinformatics prediction combined with luciferase reporter assay were used to verify whether the cyclin-dependent kinase inhibitor CDKN1A was a potential target gene of miR-96; According to the data of miRTarBase CDKN1A might be a candidate target gene of miR-96; In addition luciferase reporter and Western blot assays respectively demonstrated that miR-96 could bind to the putative seed region in CDKN1A mRNA 3'UTR and significantly reduce the expression level of CDKN1A protein; Moreover we found that the inhibition of miR-96 expression remarkably decreased cell proliferation and promoted cell apoptosis of BC cell lines which was consistent with the findings observed following the introduction of CDKN1A cDNA without 3'UTR restored miR-96; Upregulation of miR-96 may contribute to aggressive malignancy partly through suppressing CDKN1A protein expression in BC cells
76 hsa-miR-98-5p CDKN1A 1.11 0 -1.29 0 miRNAWalker2 validate -0.25 0.00026 NA
77 hsa-miR-221-3p CDKN1B 0.45 0.09098 0.11 0.45385 miRNAWalker2 validate; miRTarBase -0.11 6.0E-5 23637992; 19953484; 23939688; 19126397; 20146005; 23967190; 17569667; 22992757; 17721077; 20461750 miR-221 knockdown not only blocked cell cycle progression induced cell apoptosis and inhibited cell proliferation in-vitro but it also inhibited in-vivo tumor growth by targeting p27kip1;Based on bioinformatic analysis we found that the seed sequences of miR-221 and miR-222 coincide with each other and p27kip1 is a target for miRNA-221/222;A Slug/miR-221 network has been suggested linking miR-221 activity with the downregulation of a Slug repressor leading to Slug/miR-221 upregulation and p27Kip1 downregulation; Interference with this process can be achieved using antisense miRNA antagomiR molecules targeting miR-221 inducing the downregulation of Slug and the upregulation of p27Kip1;Moreover a series of functional assays demonstrated that mir-221 could directly inhibit cKit p27Kip1 and possibly other pivotal proteins in melanoma;Matched HCC and adjacent non-cancerous samples were assayed for the expression of miR-221 and three G1/S transition inhibitors: p27Kip1 p21WAF1/Cip1and TGF-β1 by in situ hybridization and immunohistochemistry respectively; Real time qRT-PCR was used to investigate miR-221 and p27Kip1 transcripts in different clinical stages; In result miR-221 and TGF-β1 are frequently up-regulated in HCC while p27Kip1 and p21WAF1/Cip1 proteins are frequently down-regulated; In conclusion miR-221 is important in tumorigenesis of HCC possibly by specifically down-regulating p27Kip1 a cell-cycle inhibitor;Additionally the PDGF-dependent increase in cell proliferation appears to be mediated by inhibition of a specific target of miR-221 and down-regulation of p27Kip1;miR 221 and miR 222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1; In all cell lines tested we show an inverse relationship between the expression of miR-221 and miR-222 and the cell cycle inhibitor p27Kip1; Consistently miR-221 and miR-222 knock-down through antisense LNA oligonucleotides increases p27Kip1 in PC3 cells and strongly reduces their clonogenicity in vitro;Peptide nucleic acids targeting miR 221 modulate p27Kip1 expression in breast cancer MDA MB 231 cells; Targeting miR-221 by PNA resulted in i lowering of the hybridization levels of miR-221 measured by RT-qPCR ii upregulation of p27Kip1 gene expression measured by RT-qPCR and western blot analysis;Antagonism of either microRNA 221 or 222 in glioblastoma cells also caused an increase in p27Kip1 levels and enhanced expression of the luciferase reporter gene fused to the p27Kip1 3'UTR;MiR 221 and MiR 222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B CDKNIC and overall survival; miR-221 and miR-222 negatively regulate expression of CDKN1B p27 and CDKN1C p57 two cell cycle regulators expressed in ovarian surface epithelium and down-regulated in ovarian carcinomas; In contrast CDKN1B expression was not associated with miR-221 or miR-222 expression
78 hsa-miR-24-3p CDKN1B 1 0 0.11 0.45385 miRNAWalker2 validate -0.16 3.0E-5 26847530; 26044523 The biological significance of miR-24 expression in prostate cancer cells was assessed by a series of in vitro bioassays and the effect on proposed targets p27 CDKN1B and p16 CDK2NA was investigated;With the bioinformatic method we further identified that p27Kip1 is a direct target of miR-24-3p and its protein level was negatively regulated by miR-24-3p
79 hsa-miR-221-3p CDKN1C 0.45 0.09098 -1.45 4.0E-5 miRNAWalker2 validate; miRTarBase -0.25 0.00011 20461750 miR-221 and miR-222 negatively regulate expression of CDKN1B p27 and CDKN1C p57 two cell cycle regulators expressed in ovarian surface epithelium and down-regulated in ovarian carcinomas; Higher miR-222 and miR-221 expression were significantly associated with decreased CDKN1C expression P = 0.009 and 0.01
80 hsa-miR-222-3p CDKN1C 0.85 0.00267 -1.45 4.0E-5 miRNAWalker2 validate; miRTarBase -0.25 4.0E-5 20461750 miR-221 and miR-222 negatively regulate expression of CDKN1B p27 and CDKN1C p57 two cell cycle regulators expressed in ovarian surface epithelium and down-regulated in ovarian carcinomas; Higher miR-222 and miR-221 expression were significantly associated with decreased CDKN1C expression P = 0.009 and 0.01
81 hsa-miR-25-3p CDKN1C 1.36 0 -1.45 4.0E-5 miRNAWalker2 validate; miRTarBase -0.16 0.04449 NA
82 hsa-miR-335-5p CDKN1C 1.77 0 -1.45 4.0E-5 miRNAWalker2 validate -0.1 0.02146 NA
83 hsa-miR-10b-5p CDKN2A -0.16 0.55501 2.5 0.00259 miRNAWalker2 validate; miRTarBase -0.4 0.01005 NA
84 hsa-miR-34a-5p CDKN2C 1.9 0 0.23 0.43313 miRNAWalker2 validate -0.22 6.0E-5 NA
85 hsa-miR-148a-3p DNAJB4 1.27 0 -1.87 0 miRNAWalker2 validate -0.18 3.0E-5 NA
86 hsa-miR-23b-3p E2F1 -0.25 0.1502 2.3 0 miRNAWalker2 validate -0.37 1.0E-5 NA
87 hsa-miR-125b-5p E2F3 -1.16 0.00029 0.86 0.00039 miRNAWalker2 validate; miRTarBase -0.14 9.0E-5 20549700; 22523546 E2F3 which was critical for G1/S transition and was overexpressed in most of poor-differentiated bladder cancers was identified as a target of miR-125b by luciferase assay; Introduction of miR-125b could reduce the expression of E2F3 protein but not the E2F3 mRNA;Moreover we demonstrated that the E2F3 was a direct target of miR-125b in breast cancer cells
88 hsa-miR-140-5p EP300 0.84 4.0E-5 -0.26 0.13065 miRNAWalker2 validate -0.12 0.00415 NA
89 hsa-miR-193b-3p EP300 2.26 0 -0.26 0.13065 miRNAWalker2 validate -0.11 8.0E-5 NA
90 hsa-miR-374a-5p GADD45A 0.48 0.0043 -0.84 0.00014 miRNAWalker2 validate; miRTarBase -0.16 0.01486 NA
91 hsa-miR-148a-3p GOLIM4 1.27 0 -0.33 0.26739 miRNAWalker2 validate -0.14 0.01071 NA
92 hsa-miR-145-5p HDAC2 -1.55 0 0.31 0.0174 miRNAWalker2 validate -0.11 0 23499894 MiR 145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer; Ectopic expression of miRNA mimics evidenced that miR-145 suppresses HDAC2 expression in HCC cells; In conclusion we suggest that loss or suppression of miR-145 may cause aberrant overexpression of HDAC2 and promote HCC tumorigenesis
93 hsa-miR-148a-3p IRS1 1.27 0 -0.85 0.00822 miRNAWalker2 validate; miRTarBase -0.13 0.01963 NA
94 hsa-miR-148a-3p MTMR9 1.27 0 -0.84 0 miRNAWalker2 validate -0.14 0 NA
95 hsa-let-7f-5p MYC 0.5 0.00356 -1.77 0 miRNAWalker2 validate -0.3 0.00594 NA
96 hsa-let-7g-5p MYC 1.2 0 -1.77 0 miRNAWalker2 validate; miRTarBase -0.65 0 NA
97 hsa-miR-320a MYC 0.44 0.03902 -1.77 0 miRNAWalker2 validate -0.27 0.00203 25736597 Furthermore progesterone P4 promoted the expression of miR-320a by repressing c-Myc expression while estrogen E2 exerted the opposite effect
98 hsa-miR-320b MYC 1.56 0 -1.77 0 miRNAWalker2 validate -0.21 0.00143 26487644 miR 320b suppresses cell proliferation by targeting c Myc in human colorectal cancer cells; Overexpression of miR-320b in CRC cells was statistically correlated with a decrease of cell growth in vitro and in vivo while c-MYC was identified as a target gene of miR-320b in CRC; Furthermore it was found that up-regulation of c-Myc can attenuate the effects induced by miR-320b; Our identification of c-MYC as a target gene of miR-320b provides new insights into the pathophysiology of CRC proliferation and identifies miR-320b as a novel therapeutic target for the treatment of CRC
99 hsa-miR-335-5p MYC 1.77 0 -1.77 0 miRNAWalker2 validate -0.16 0.00141 NA
100 hsa-miR-34a-5p MYC 1.9 0 -1.77 0 miRNAWalker2 validate; miRTarBase -0.36 0 25572695; 25686834; 21460242; 22159222; 23640973; 22830357; 22235332 The c-Myc and CD44 were confirmed as direct targets of miR-34a in EJ cell apoptosis induced by PRE;miR 34a induces cellular senescence via modulation of telomerase activity in human hepatocellular carcinoma by targeting FoxM1/c Myc pathway;Myc mediated repression of microRNA 34a promotes high grade transformation of B cell lymphoma by dysregulation of FoxP1;MicroRNA 34a suppresses malignant transformation by targeting c Myc transcriptional complexes in human renal cell carcinoma; We investigated the functional effects of microRNA-34a miR-34a on c-Myc transcriptional complexes in renal cell carcinoma; miR-34a down-regulated expression of multiple oncogenes including c-Myc by targeting its 3' untranslated region which was revealed by luciferase reporter assays; Our results demonstrate that miR-34a suppresses assembly and function of the c-Myc complex that activates or elongates transcription indicating a novel role of miR-34a in the regulation of transcription by c-Myc;Among them miR-34a was also associated with poor prognosis in 2 independent series of leukemic and nodal MCL and in cooperation with high expression of the MYC oncogene;We report that miR-34a did not inhibit cell proliferation notwithstanding a marked down-regulation of c-MYC;MicroRNA 34a modulates c Myc transcriptional complexes to suppress malignancy in human prostate cancer cells; We studied the functional effects of miR-34a on c-Myc transcriptional complexes in PC-3 prostate cancer cells; miR-34a downregulated expression of c-Myc oncogene by targeting its 3' UTR as shown by luciferase reporter assays; This is the first report to document that miR-34a suppresses assembly and function of the c-Myc-Skp2-Miz1 complex that activates RhoA and the c-Myc-pTEFB complex that elongates transcription of various genes suggesting a novel role of miR-34a in the regulation of transcription by c-Myc complex
101 hsa-miR-423-5p MYC 0.96 0 -1.77 0 miRNAWalker2 validate -0.59 0 NA
102 hsa-miR-429 MYC 4.49 0 -1.77 0 miRNAWalker2 validate -0.27 0 21684154; 24633485 miR 429 modulates the expression of c myc in human gastric carcinoma cells; SGC-7901 gastric cancer cells were transfected with miR-429 mimics and endogenous c-myc expression was detected by western blots; We performed functional assays using the 3'UTR of the c-myc gene as a miR-429 target in a luciferase reporter assay system; miR-429 significantly downregulated endogenous c-myc expression in SGC-7901 cells; Action of miR/429 on c-myc 3'UTR was confirmed; c-myc is an important miR-429 target gene;It is known that miR-429 is down-regulated and functions as a tumor suppressor by targeting c-myc and PLGG1 in gastric and breast cancer
103 hsa-miR-744-5p MYC 1.48 0 -1.77 0 miRNAWalker2 validate -0.25 0.00044 24991193 Decrease expression of microRNA 744 promotes cell proliferation by targeting c Myc in human hepatocellular carcinoma; Quantitative reverse-transcription polymerase chain reaction qRT-PCR was conducted to detect the expression of miR-744 and Immunohistochemistry was performed to detect expression of c-Myc in HCC specimens and adjacent normal tissues; Luciferase reporter assays was performed to confirm whether miR-744 regulated the expression of c-Myc; Luciferase assay and Western blot analysis revealed that c-Myc is a direct target of miR-744; Down-regulation of miR-744 and up-regulation of c-Myc were detected in HCC specimens compared with adjacent normal tissues; Moreover restoration of miR-744 rescues c-Myc induced HCC proliferation; Our data suggest that miR-744 exerts its tumor suppressor function by targeting c-Myc leading to the inhibition of HCC cell growth
104 hsa-miR-98-5p MYC 1.11 0 -1.77 0 miRNAWalker2 validate; miRTarBase -0.6 0 NA
105 hsa-miR-148a-3p PRNP 1.27 0 -0.93 0.0083 miRNAWalker2 validate -0.2 0.00154 NA
106 hsa-miR-148a-3p RASSF8 1.27 0 -1.49 0 miRNAWalker2 validate -0.22 0.00018 NA
107 hsa-miR-106a-5p RB1 2.49 0 -0.45 0.06418 miRNAWalker2 validate; miRTarBase -0.21 0 NA
108 hsa-miR-106b-5p RB1 2.47 0 -0.45 0.06418 miRNAWalker2 validate; miRTarBase -0.18 8.0E-5 NA
109 hsa-miR-17-5p RB1 3.27 0 -0.45 0.06418 miRNAWalker2 validate; miRTarBase; TargetScan -0.18 0 NA
110 hsa-miR-192-5p RB1 2.69 0 -0.45 0.06418 miRNAWalker2 validate; miRTarBase -0.15 1.0E-5 NA
111 hsa-miR-20a-5p RB1 3.16 0 -0.45 0.06418 miRNAWalker2 validate; miRTarBase -0.18 0 NA
112 hsa-miR-93-5p RB1 3.04 0 -0.45 0.06418 miRNAWalker2 validate -0.17 1.0E-5 NA
113 hsa-miR-148a-3p RPS6KA5 1.27 0 -1.71 0 miRNAWalker2 validate; miRTarBase -0.14 0.00809 20406806 MiR 148a attenuates paclitaxel resistance of hormone refractory drug resistant prostate cancer PC3 cells by regulating MSK1 expression; Computer-aided algorithms predicted mitogen- and stress-activated protein kinase MSK1 as a potential target of miR-148a; Indeed miR-148a overexpression decreased expression of MSK1; Using luciferase reporter assays we identified MSK1 as a direct target of miR-148a; MiR-148a reduced MSK1 expression by directly targeting its 3'-UTR in PC3PR cells; Furthermore MSK1 knockdown reduced paclitaxel-resistance of PC3PR cells indicating that miR-148a attenuates paclitaxel-resistance of hormone-refractory drug-resistant PC3PR cells in part by regulating MSK1 expression
114 hsa-miR-148a-3p SECISBP2L 1.27 0 -0.85 0 miRNAWalker2 validate -0.13 3.0E-5 NA
115 hsa-miR-148a-3p SESTD1 1.27 0 -0.83 0.00021 miRNAWalker2 validate -0.12 0.0023 NA
116 hsa-miR-155-5p SMAD3 1.2 0.00086 -0.15 0.56924 miRNAWalker2 validate -0.17 0 27626488 Here we demonstrated that TGF-β1 elevated the expression of miR-155 in colorectal cancer cells through SMAD3 and SMAD4
117 hsa-miR-18a-5p SMAD3 3.79 0 -0.15 0.56924 miRNAWalker2 validate -0.14 6.0E-5 23249750 The unexpected effects of miR-18a on CTGF transcription are mediated in part by direct targeting of Smad3 and ensuing weakening of TGFβ signaling
118 hsa-miR-186-5p SMAD4 1.47 0 -0.59 0 miRNAWalker2 validate -0.11 0.00087 NA
119 hsa-miR-320a SMC1A 0.44 0.03902 0.04 0.7733 miRNAWalker2 validate -0.12 0.00036 NA
120 hsa-miR-148a-3p SPRY2 1.27 0 -1.57 0 miRNAWalker2 validate -0.14 0.01168 NA
121 hsa-miR-26b-5p STAG1 0.89 0 -0.25 0.20245 miRNAWalker2 validate -0.17 0.00045 NA
122 hsa-miR-21-5p STAG2 2.74 0 -0.34 0.12258 miRNAWalker2 validate -0.12 0.01253 NA
123 hsa-miR-744-5p TGFB1 1.48 0 -0 0.99941 miRNAWalker2 validate -0.23 1.0E-5 NA
124 hsa-miR-141-3p TGFB2 5.02 0 -1.2 0.00331 miRNAWalker2 validate; miRTarBase; TargetScan -0.36 0 NA
125 hsa-miR-29b-3p TGFB2 1.66 0 -1.2 0.00331 miRTarBase -0.23 0.00122 NA
126 hsa-miR-335-5p TGFB2 1.77 0 -1.2 0.00331 miRNAWalker2 validate -0.25 0 NA
127 hsa-miR-10a-5p TGFB3 1.15 0.00372 -1.92 0 miRNAWalker2 validate -0.42 0 NA
128 hsa-miR-29b-3p TGFB3 1.66 0 -1.92 0 miRTarBase -0.4 0 NA
129 hsa-miR-221-3p TP53 0.45 0.09098 0.17 0.48779 miRNAWalker2 validate -0.12 0.01057 20880178; 24324033 Circulating miR 221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression; The correlation between miR-221 levels and protein levels of p53 CEA ER and PR clinicopathological features or overall survival was analyzed; The immunohistochemistry analysis demonstrates a significant correlation between plasma miR-221 level and p53 expression; The direct amplification of plasma miR-221 can be used as a potential noninvasive molecular marker for diagnosis and prognosis of CRC and is correlated with p53 expression;Interestingly miR-221 can activate the p53/mdm2 axis by inhibiting MDM2 and in turn p53 activation contributes to miR-221 enhanced expression; Moreover by modulating the p53 axis miR-221 impacts cell-cycle progression and apoptotic response to doxorubicin in hepatocellular carcinoma-derived cell lines; These data were confirmed in clinical specimens of hepatocellular carcinoma in which elevated miR-221 expression was associated with the simultaneous presence of wild-type p53 and DNA hypomethylation
130 hsa-miR-222-3p TP53 0.85 0.00267 0.17 0.48779 miRNAWalker2 validate -0.12 0.0059 NA
131 hsa-miR-155-5p WEE1 1.2 0.00086 -1.41 0 miRNAWalker2 validate -0.12 3.0E-5 NA
132 hsa-miR-27a-3p WEE1 1.67 0 -1.41 0 miRTarBase -0.15 0.00064 NA
133 hsa-miR-424-5p WEE1 1.62 0 -1.41 0 miRNAWalker2 validate; miRTarBase -0.13 0.00073 NA
134 hsa-miR-26a-5p YWHAE 0.05 0.75263 0.51 0.00018 miRNAWalker2 validate -0.17 0.00016 NA
135 hsa-miR-103a-3p YWHAH 1.44 0 -0.04 0.78793 miRNAWalker2 validate -0.16 0 NA
NumGOOverlapSizeP ValueAdj. P Value
1 CELL CYCLE 35 1316 7.773e-31 3.617e-27
2 CELL CYCLE PROCESS 32 1081 4.851e-29 1.129e-25
3 REGULATION OF CELL CYCLE 30 949 9.881e-28 1.533e-24
4 MITOTIC CELL CYCLE 27 766 7.978e-26 9.28e-23
5 NEGATIVE REGULATION OF CELL CYCLE 23 433 1.01e-25 9.401e-23
6 CELL CYCLE ARREST 17 154 2.499e-24 1.938e-21
7 REGULATION OF PROTEIN MODIFICATION PROCESS 31 1710 1.517e-21 1.009e-18
8 REGULATION OF PHOSPHORUS METABOLIC PROCESS 30 1618 5.563e-21 3.235e-18
9 REGULATION OF CELL PROLIFERATION 28 1496 1.939e-19 1.003e-16
10 NEGATIVE REGULATION OF CELL PROLIFERATION 21 643 5.456e-19 2.539e-16
11 CELL CYCLE PHASE TRANSITION 16 255 6.993e-19 2.547e-16
12 NEGATIVE REGULATION OF MITOTIC CELL CYCLE 15 199 6.37e-19 2.547e-16
13 REGULATION OF MITOTIC CELL CYCLE 19 468 7.116e-19 2.547e-16
14 POSITIVE REGULATION OF CELL CYCLE 17 332 1.473e-18 4.896e-16
15 REGULATION OF TRANSFERASE ACTIVITY 23 946 4.624e-18 1.435e-15
16 NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS 20 616 5.35e-18 1.556e-15
17 MITOTIC CELL CYCLE CHECKPOINT 13 139 1.056e-17 2.89e-15
18 NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS 23 1087 9.729e-17 2.515e-14
19 CELL DIVISION 17 460 3.477e-16 8.516e-14
20 POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 25 1492 5.96e-16 1.387e-13
21 CELL CYCLE CHECKPOINT 13 194 8.679e-16 1.923e-13
22 REGULATION OF CELL CYCLE ARREST 11 108 1.658e-15 3.507e-13
23 CELL CYCLE G1 S PHASE TRANSITION 11 111 2.263e-15 4.387e-13
24 G1 S TRANSITION OF MITOTIC CELL CYCLE 11 111 2.263e-15 4.387e-13
25 NEGATIVE REGULATION OF CELL CYCLE PROCESS 13 214 3.125e-15 5.816e-13
26 POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS 22 1135 3.615e-15 6.469e-13
27 NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 17 541 5.059e-15 8.406e-13
28 NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 17 541 5.059e-15 8.406e-13
29 POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 21 1036 8.027e-15 1.167e-12
30 REGULATION OF KINASE ACTIVITY 19 776 7.819e-15 1.167e-12
31 POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 21 1036 8.027e-15 1.167e-12
32 POSITIVE REGULATION OF CELL CYCLE ARREST 10 85 7.994e-15 1.167e-12
33 REGULATION OF CELL CYCLE PROCESS 17 558 8.403e-15 1.185e-12
34 POSITIVE REGULATION OF CELL CYCLE PROCESS 13 247 2.006e-14 2.745e-12
35 REGULATION OF CELL CYCLE PHASE TRANSITION 14 321 2.311e-14 3.072e-12
36 SIGNAL TRANSDUCTION IN RESPONSE TO DNA DAMAGE 10 96 2.826e-14 3.652e-12
37 POSITIVE REGULATION OF CELL DEATH 17 605 3.149e-14 3.96e-12
38 NEGATIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION 10 98 3.496e-14 4.281e-12
39 NEGATIVE REGULATION OF PHOSPHORYLATION 15 422 4.679e-14 5.582e-12
40 NEGATIVE REGULATION OF CELL CYCLE PHASE TRANSITION 11 146 4.921e-14 5.724e-12
41 NEGATIVE REGULATION OF TRANSFERASE ACTIVITY 14 351 7.875e-14 8.937e-12
42 G1 DNA DAMAGE CHECKPOINT 9 73 1.262e-13 1.398e-11
43 NEGATIVE REGULATION OF MOLECULAR FUNCTION 20 1079 2.327e-13 2.518e-11
44 REGULATION OF CELL DEATH 22 1472 7.272e-13 7.69e-11
45 REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 9 97 1.779e-12 1.839e-10
46 REGULATION OF CELL CYCLE G1 S PHASE TRANSITION 10 147 2.172e-12 2.197e-10
47 MITOTIC DNA INTEGRITY CHECKPOINT 9 100 2.355e-12 2.331e-10
48 REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 14 470 4.117e-12 3.991e-10
49 NEGATIVE REGULATION OF CATALYTIC ACTIVITY 17 829 4.999e-12 4.747e-10
50 RESPONSE TO OXYGEN LEVELS 12 311 8.926e-12 8.306e-10
51 RESPONSE TO ABIOTIC STIMULUS 18 1024 1.29e-11 1.155e-09
52 REGULATION OF ORGANELLE ORGANIZATION 19 1178 1.29e-11 1.155e-09
53 NEGATIVE REGULATION OF KINASE ACTIVITY 11 250 1.79e-11 1.572e-09
54 REGULATION OF CELLULAR PROTEIN LOCALIZATION 14 552 3.513e-11 3.027e-09
55 REGULATION OF PROTEIN LOCALIZATION 17 950 4.279e-11 3.62e-09
56 POSITIVE REGULATION OF CELL PROLIFERATION 16 814 4.659e-11 3.871e-09
57 DNA INTEGRITY CHECKPOINT 9 146 7.357e-11 6.006e-09
58 POSITIVE REGULATION OF KINASE ACTIVITY 13 482 9.382e-11 7.527e-09
59 POSITIVE REGULATION OF TRANSFERASE ACTIVITY 14 616 1.492e-10 1.177e-08
60 POSITIVE REGULATION OF GENE EXPRESSION 21 1733 1.588e-10 1.232e-08
61 POSITIVE REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION 6 34 2.011e-10 1.534e-08
62 NEGATIVE REGULATION OF CELL GROWTH 9 170 2.873e-10 2.156e-08
63 POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 21 1805 3.38e-10 2.497e-08
64 RESPONSE TO DRUG 12 431 3.865e-10 2.81e-08
65 NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 8 126 7.201e-10 5.155e-08
66 REGULATION OF CELL DIFFERENTIATION 19 1492 7.368e-10 5.194e-08
67 SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 8 127 7.671e-10 5.327e-08
68 POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 17 1152 8.452e-10 5.783e-08
69 POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION 11 360 8.724e-10 5.883e-08
70 MITOTIC NUCLEAR DIVISION 11 361 8.982e-10 5.971e-08
71 CELL DEATH 16 1001 9.688e-10 6.297e-08
72 NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS 19 1517 9.743e-10 6.297e-08
73 POSITIVE REGULATION OF RESPONSE TO STIMULUS 21 1929 1.147e-09 7.312e-08
74 ORGANELLE FISSION 12 496 1.901e-09 1.195e-07
75 REGULATION OF CELL GROWTH 11 391 2.074e-09 1.287e-07
76 POSITIVE REGULATION OF STEM CELL DIFFERENTIATION 6 50 2.307e-09 1.412e-07
77 DIGESTIVE SYSTEM DEVELOPMENT 8 148 2.594e-09 1.567e-07
78 CELL DEVELOPMENT 18 1426 2.8e-09 1.67e-07
79 RESPONSE TO ENDOGENOUS STIMULUS 18 1450 3.648e-09 2.149e-07
80 NEGATIVE REGULATION OF GROWTH 9 236 5.19e-09 3.018e-07
81 REGULATION OF DNA METABOLIC PROCESS 10 340 8.063e-09 4.632e-07
82 POSITIVE REGULATION OF CELL COMMUNICATION 18 1532 8.683e-09 4.927e-07
83 POSITIVE REGULATION OF ORGANELLE ORGANIZATION 12 573 9.566e-09 5.363e-07
84 CELLULAR RESPONSE TO ENDOGENOUS STIMULUS 15 1008 9.732e-09 5.391e-07
85 CELLULAR RESPONSE TO DNA DAMAGE STIMULUS 13 720 1.215e-08 6.653e-07
86 INTRACELLULAR SIGNAL TRANSDUCTION 18 1572 1.3e-08 7.03e-07
87 NEGATIVE REGULATION OF CELL DEATH 14 872 1.314e-08 7.03e-07
88 REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION 6 67 1.404e-08 7.423e-07
89 POSITIVE REGULATION OF MOLECULAR FUNCTION 19 1791 1.526e-08 7.975e-07
90 RESPONSE TO GROWTH FACTOR 11 475 1.56e-08 7.975e-07
91 REPLICATIVE SENESCENCE 4 12 1.551e-08 7.975e-07
92 NEUROGENESIS 17 1402 1.632e-08 8.253e-07
93 RESPONSE TO LIPID 14 888 1.653e-08 8.272e-07
94 POSITIVE REGULATION OF INTRACELLULAR TRANSPORT 10 370 1.799e-08 8.813e-07
95 REGULATION OF CELL DIVISION 9 272 1.781e-08 8.813e-07
96 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE 6 71 2e-08 9.693e-07
97 REGULATION OF CHROMOSOME ORGANIZATION 9 278 2.15e-08 1.031e-06
98 REGULATION OF INTRACELLULAR TRANSPORT 12 621 2.331e-08 1.107e-06
99 RESPONSE TO STEROID HORMONE 11 497 2.481e-08 1.155e-06
100 RESPONSE TO ORGANIC CYCLIC COMPOUND 14 917 2.476e-08 1.155e-06
101 POSITIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 5 36 2.548e-08 1.174e-06
102 REGULATION OF EPITHELIAL CELL PROLIFERATION 9 285 2.664e-08 1.215e-06
103 POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS 7 129 2.703e-08 1.221e-06
104 APOPTOTIC SIGNALING PATHWAY 9 289 3.004e-08 1.344e-06
105 REGULATION OF CELLULAR LOCALIZATION 16 1277 3.121e-08 1.383e-06
106 GLAND DEVELOPMENT 10 395 3.334e-08 1.463e-06
107 POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION 11 514 3.498e-08 1.521e-06
108 REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 8 207 3.604e-08 1.553e-06
109 NEGATIVE REGULATION OF GENE EXPRESSION 17 1493 4.13e-08 1.763e-06
110 CELL CYCLE G2 M PHASE TRANSITION 7 138 4.31e-08 1.823e-06
111 REGULATION OF FIBROBLAST PROLIFERATION 6 81 4.449e-08 1.865e-06
112 POSITIVE REGULATION OF CATALYTIC ACTIVITY 17 1518 5.268e-08 2.189e-06
113 REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS 8 218 5.382e-08 2.216e-06
114 REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 8 220 5.776e-08 2.338e-06
115 RESPONSE TO TRANSFORMING GROWTH FACTOR BETA 7 144 5.78e-08 2.338e-06
116 POSITIVE REGULATION OF CHROMATIN MODIFICATION 6 85 5.951e-08 2.387e-06
117 TUBE DEVELOPMENT 11 552 7.22e-08 2.871e-06
118 POSITIVE REGULATION OF CHROMOSOME ORGANIZATION 7 150 7.652e-08 2.997e-06
119 POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 14 1004 7.666e-08 2.997e-06
120 REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 9 337 1.117e-07 4.333e-06
121 POSITIVE REGULATION OF PATHWAY RESTRICTED SMAD PROTEIN PHOSPHORYLATION 5 48 1.132e-07 4.353e-06
122 TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY 6 95 1.161e-07 4.428e-06
123 REGULATION OF DNA REPLICATION 7 161 1.243e-07 4.702e-06
124 POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 7 162 1.297e-07 4.865e-06
125 CELLULAR RESPONSE TO ORGANIC SUBSTANCE 18 1848 1.566e-07 5.827e-06
126 POSITIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 6 100 1.578e-07 5.827e-06
127 POSITIVE REGULATION OF FIBROBLAST PROLIFERATION 5 53 1.88e-07 6.888e-06
128 REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 17 1672 2.14e-07 7.778e-06
129 NEGATIVE REGULATION OF DNA REPLICATION 5 55 2.271e-07 8.19e-06
130 SMAD PROTEIN SIGNAL TRANSDUCTION 5 56 2.489e-07 8.908e-06
131 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL METABOLIC PROCESS 4 23 2.72e-07 9.589e-06
132 POSITIVE REGULATION OF COLLAGEN METABOLIC PROCESS 4 23 2.72e-07 9.589e-06
133 REGULATION OF GROWTH 11 633 2.856e-07 9.954e-06
134 PROTEIN PHOSPHORYLATION 13 944 2.867e-07 9.954e-06
135 EPITHELIUM DEVELOPMENT 13 945 2.901e-07 1e-05
136 NEGATIVE REGULATION OF DNA METABOLIC PROCESS 6 111 2.937e-07 1.005e-05
137 REGULATION OF STEM CELL DIFFERENTIATION 6 113 3.265e-07 1.109e-05
138 REGULATION OF PATHWAY RESTRICTED SMAD PROTEIN PHOSPHORYLATION 5 60 3.532e-07 1.191e-05
139 NEGATIVE REGULATION OF EPITHELIAL CELL PROLIFERATION 6 115 3.623e-07 1.213e-05
140 NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS 12 801 3.693e-07 1.227e-05
141 POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 14 1142 3.717e-07 1.227e-05
142 REGULATION OF BINDING 8 283 3.971e-07 1.301e-05
143 POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 8 289 4.655e-07 1.515e-05
144 REGULATION OF PROTEIN ACETYLATION 5 64 4.895e-07 1.571e-05
145 POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 6 121 4.894e-07 1.571e-05
146 NEGATIVE REGULATION OF RESPONSE TO STIMULUS 15 1360 4.958e-07 1.58e-05
147 REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 17 1784 5.395e-07 1.708e-05
148 GROWTH 9 410 5.825e-07 1.831e-05
149 CHROMOSOME ORGANIZATION 13 1009 6.119e-07 1.91e-05
150 PEPTIDYL AMINO ACID MODIFICATION 12 841 6.202e-07 1.91e-05
151 RESPONSE TO RADIATION 9 413 6.19e-07 1.91e-05
152 NEGATIVE REGULATION OF CELL COMMUNICATION 14 1192 6.238e-07 1.91e-05
153 REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY 4 29 7.218e-07 2.153e-05
154 POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY 4 29 7.218e-07 2.153e-05
155 REGULATION OF EXTRACELLULAR MATRIX ORGANIZATION 4 29 7.218e-07 2.153e-05
156 REGULATION OF HEART MORPHOGENESIS 4 29 7.218e-07 2.153e-05
157 REGULATION OF CYTOKINE PRODUCTION 10 563 8.825e-07 2.615e-05
158 REGULATION OF PROTEOLYSIS 11 711 9.009e-07 2.653e-05
159 CELLULAR RESPONSE TO RADIATION 6 137 1.016e-06 2.973e-05
160 NEGATIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 4 32 1.087e-06 3.161e-05
161 RESPONSE TO HORMONE 12 893 1.168e-06 3.375e-05
162 REGULATION OF CATABOLIC PROCESS 11 731 1.182e-06 3.395e-05
163 IMMUNE SYSTEM DEVELOPMENT 10 582 1.191e-06 3.401e-05
164 NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 11 740 1.332e-06 3.779e-05
165 REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS 7 229 1.343e-06 3.788e-05
166 RESPONSE TO IONIZING RADIATION 6 145 1.416e-06 3.969e-05
167 CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND 9 465 1.653e-06 4.607e-05
168 REPRODUCTION 14 1297 1.709e-06 4.734e-05
169 POSITIVE REGULATION OF PROTEIN ACETYLATION 4 36 1.768e-06 4.838e-05
170 POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY 4 36 1.768e-06 4.838e-05
171 NEGATIVE REGULATION OF CELL DIFFERENTIATION 10 609 1.792e-06 4.876e-05
172 INTRINSIC APOPTOTIC SIGNALING PATHWAY 6 152 1.864e-06 5.013e-05
173 REGULATION OF CHROMATIN ORGANIZATION 6 152 1.864e-06 5.013e-05
174 POSITIVE REGULATION OF TRANSPORT 12 936 1.91e-06 5.08e-05
175 POSITIVE REGULATION OF OSSIFICATION 5 84 1.911e-06 5.08e-05
176 POSITIVE REGULATION OF BIOMINERAL TISSUE DEVELOPMENT 4 38 2.207e-06 5.77e-05
177 REGULATION OF CYTOPLASMIC TRANSPORT 9 481 2.183e-06 5.77e-05
178 REGULATION OF MULTICELLULAR ORGANISMAL METABOLIC PROCESS 4 38 2.207e-06 5.77e-05
179 RESPONSE TO ALCOHOL 8 362 2.517e-06 6.542e-05
180 POSITIVE REGULATION OF PROTEOLYSIS 8 363 2.569e-06 6.64e-05
181 SENSORY ORGAN DEVELOPMENT 9 493 2.671e-06 6.866e-05
182 REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 6 162 2.699e-06 6.899e-05
183 CELLULAR RESPONSE TO STRESS 15 1565 2.908e-06 7.394e-05
184 REGULATION OF MACROPHAGE CYTOKINE PRODUCTION 3 12 2.994e-06 7.529e-05
185 POSITIVE REGULATION OF SMAD PROTEIN IMPORT INTO NUCLEUS 3 12 2.994e-06 7.529e-05
186 NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS 8 372 3.079e-06 7.702e-05
187 NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 12 983 3.175e-06 7.899e-05
188 AGING 7 264 3.451e-06 8.541e-05
189 REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 8 381 3.673e-06 8.988e-05
190 REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY 4 43 3.657e-06 8.988e-05
191 POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY 6 171 3.69e-06 8.988e-05
192 PATHWAY RESTRICTED SMAD PROTEIN PHOSPHORYLATION 3 13 3.885e-06 9.366e-05
193 MITOTIC CELL CYCLE ARREST 3 13 3.885e-06 9.366e-05
194 REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY 5 99 4.307e-06 0.0001022
195 REGULATION OF IMMUNE SYSTEM PROCESS 14 1403 4.299e-06 0.0001022
196 REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS 5 99 4.307e-06 0.0001022
197 REGULATION OF PROTEIN CATABOLIC PROCESS 8 393 4.615e-06 0.000109
198 REGULATION OF OSSIFICATION 6 178 4.65e-06 0.0001093
199 NEGATIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 5 102 4.988e-06 0.0001166
200 NEURON DEVELOPMENT 10 687 5.238e-06 0.0001219
201 RESPONSE TO KETONE 6 182 5.284e-06 0.0001223
202 POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT 7 282 5.324e-06 0.0001226
203 REGULATION OF PROTEIN IMPORT 6 183 5.453e-06 0.0001244
204 PHOSPHORYLATION 13 1228 5.442e-06 0.0001244
205 POSITIVE REGULATION OF PROTEIN IMPORT 5 104 5.487e-06 0.0001245
206 REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 15 1656 5.836e-06 0.0001317
207 POSITIVE REGULATION OF CELLULAR COMPONENT BIOGENESIS 8 406 5.86e-06 0.0001317
208 MEIOTIC CELL CYCLE 6 186 5.987e-06 0.0001339
209 NEURON PROJECTION DEVELOPMENT 9 545 6.031e-06 0.0001343
210 REGULATION OF CELL MORPHOGENESIS 9 552 6.685e-06 0.0001481
211 TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 6 190 6.764e-06 0.0001491
212 NEGATIVE REGULATION OF PROTEIN CATABOLIC PROCESS 5 109 6.907e-06 0.000151
213 HEAD DEVELOPMENT 10 709 6.912e-06 0.000151
214 REGULATION OF SMAD PROTEIN IMPORT INTO NUCLEUS 3 16 7.568e-06 0.0001638
215 SISTER CHROMATID COHESION 5 111 7.549e-06 0.0001638
216 CELLULAR RESPONSE TO IONIZING RADIATION 4 52 7.894e-06 0.0001701
217 EMBRYO DEVELOPMENT 11 894 8.194e-06 0.0001757
218 INTRINSIC APOPTOTIC SIGNALING PATHWAY BY P53 CLASS MEDIATOR 4 53 8.523e-06 0.0001819
219 NOTCH SIGNALING PATHWAY 5 114 8.599e-06 0.0001827
220 PROTEIN SUMOYLATION 5 115 8.974e-06 0.0001898
221 POSITIVE REGULATION OF EXTRACELLULAR MATRIX ORGANIZATION 3 17 9.173e-06 0.0001931
222 REGULATION OF PROTEIN TARGETING 7 307 9.27e-06 0.0001943
223 TISSUE DEVELOPMENT 14 1518 1.067e-05 0.0002226
224 NEGATIVE REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS 5 121 1.15e-05 0.0002388
225 POSITIVE REGULATION OF MITOTIC CELL CYCLE 5 123 1.245e-05 0.0002575
226 REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 6 213 1.298e-05 0.0002672
227 REGULATION OF CELL CYCLE G2 M PHASE TRANSITION 4 59 1.31e-05 0.0002686
228 REGULATION OF CELLULAR COMPONENT BIOGENESIS 10 767 1.373e-05 0.0002801
229 CELLULAR RESPONSE TO LIPID 8 457 1.386e-05 0.0002815
230 RESPONSE TO UV 5 126 1.399e-05 0.0002831
231 RESPONSE TO ESTROGEN 6 218 1.481e-05 0.0002982
232 REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION 5 128 1.511e-05 0.0003029
233 DEVELOPMENTAL GROWTH 7 333 1.569e-05 0.0003134
234 SOMITOGENESIS 4 62 1.598e-05 0.0003177
235 REGULATION OF TRANSPORT 15 1804 1.645e-05 0.0003256
236 BRANCHING MORPHOGENESIS OF AN EPITHELIAL TUBE 5 131 1.69e-05 0.0003332
237 POSITIVE REGULATION OF CELL DIVISION 5 132 1.753e-05 0.0003442
238 LYMPHOCYTE ACTIVATION 7 342 1.863e-05 0.0003643
239 NUCLEAR CHROMOSOME SEGREGATION 6 228 1.908e-05 0.0003715
240 RESPONSE TO OXYGEN CONTAINING COMPOUND 13 1381 1.928e-05 0.0003738
241 CELLULAR RESPONSE TO UV 4 66 2.049e-05 0.0003957
242 NEGATIVE REGULATION OF CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE 3 22 2.06e-05 0.000396
243 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 13 1395 2.146e-05 0.0004109
244 POSITIVE REGULATION OF NEURON DEATH 4 67 2.175e-05 0.0004115
245 CELL AGING 4 67 2.175e-05 0.0004115
246 CELLULAR RESPONSE TO DRUG 4 67 2.175e-05 0.0004115
247 NEGATIVE REGULATION OF LEUKOCYTE PROLIFERATION 4 69 2.445e-05 0.0004606
248 POSITIVE REGULATION OF CELL DIFFERENTIATION 10 823 2.519e-05 0.0004726
249 RAS PROTEIN SIGNAL TRANSDUCTION 5 143 2.579e-05 0.0004818
250 REGULATION OF MEMBRANE PERMEABILITY 4 70 2.588e-05 0.0004818
251 REGULATION OF ORGAN MORPHOGENESIS 6 242 2.669e-05 0.0004948
252 REGULATION OF CYTOSKELETON ORGANIZATION 8 502 2.719e-05 0.000502
253 REGULATION OF APOPTOTIC SIGNALING PATHWAY 7 363 2.73e-05 0.0005021
254 REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY 7 365 2.828e-05 0.000518
255 CHROMATIN ORGANIZATION 9 663 2.87e-05 0.0005234
256 REGULATION OF CELL DEVELOPMENT 10 836 2.88e-05 0.0005234
257 ORGAN MORPHOGENESIS 10 841 3.03e-05 0.0005486
258 REGULATION OF TRANSFORMING GROWTH FACTOR BETA PRODUCTION 3 25 3.06e-05 0.0005498
259 HISTONE PHOSPHORYLATION 3 25 3.06e-05 0.0005498
260 CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 8 513 3.172e-05 0.0005677
261 REGULATION OF BIOMINERAL TISSUE DEVELOPMENT 4 75 3.401e-05 0.0006062
262 REGULATION OF CELLULAR SENESCENCE 3 26 3.453e-05 0.0006116
263 MEIOTIC CELL CYCLE PROCESS 5 152 3.457e-05 0.0006116
264 POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 6 258 3.82e-05 0.0006732
265 ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY 9 689 3.876e-05 0.0006784
266 REGULATION OF TRANSCRIPTION INVOLVED IN G1 S TRANSITION OF MITOTIC CELL CYCLE 3 27 3.878e-05 0.0006784
267 REGULATION OF CELLULAR RESPONSE TO STRESS 9 691 3.965e-05 0.0006891
268 SOMITE DEVELOPMENT 4 78 3.969e-05 0.0006891
269 NEURON DIFFERENTIATION 10 874 4.201e-05 0.0007267
270 CELLULAR RESPONSE TO ABIOTIC STIMULUS 6 263 4.251e-05 0.0007326
271 POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 10 876 4.283e-05 0.0007355
272 POSITIVE REGULATION OF LEUKOCYTE APOPTOTIC PROCESS 3 28 4.336e-05 0.0007418
273 CHROMATIN MODIFICATION 8 539 4.503e-05 0.0007675
274 REGULATION OF NUCLEAR DIVISION 5 163 4.826e-05 0.000817
275 NEGATIVE REGULATION OF PRODUCTION OF MOLECULAR MEDIATOR OF IMMUNE RESPONSE 3 29 4.828e-05 0.000817
276 ORGAN REGENERATION 4 83 5.068e-05 0.0008513
277 MORPHOGENESIS OF AN EPITHELIUM 7 400 5.057e-05 0.0008513
278 CHROMOSOME SEGREGATION 6 272 5.126e-05 0.000858
279 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE BY P53 CLASS MEDIATOR 3 30 5.356e-05 0.00089
280 RESPONSE TO X RAY 3 30 5.356e-05 0.00089
281 MORPHOGENESIS OF A BRANCHING STRUCTURE 5 167 5.416e-05 0.0008969
282 EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING 8 554 5.463e-05 0.0009015
283 REGULATION OF CELL PROJECTION ORGANIZATION 8 558 5.747e-05 0.0009449
284 POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS 4 86 5.825e-05 0.0009543
285 LEUKOCYTE ACTIVATION 7 414 6.281e-05 0.001025
286 SALIVARY GLAND DEVELOPMENT 3 32 6.52e-05 0.001053
287 ENDOCARDIAL CUSHION DEVELOPMENT 3 32 6.52e-05 0.001053
288 CELL ACTIVATION 8 568 6.509e-05 0.001053
289 SEGMENTATION 4 89 6.661e-05 0.001072
290 GLIOGENESIS 5 175 6.763e-05 0.001085
291 RESPONSE TO CORTICOSTEROID 5 176 6.948e-05 0.001105
292 SISTER CHROMATID SEGREGATION 5 176 6.948e-05 0.001105
293 MESONEPHROS DEVELOPMENT 4 90 6.959e-05 0.001105
294 CELLULAR SENESCENCE 3 33 7.16e-05 0.001129
295 REGULATION OF CELL AGING 3 33 7.16e-05 0.001129
296 CELLULAR RESPONSE TO LIGHT STIMULUS 4 91 7.265e-05 0.001142
297 MITOCHONDRIAL MEMBRANE ORGANIZATION 4 92 7.582e-05 0.001188
298 REGULATION OF PROTEIN DEACETYLATION 3 34 7.839e-05 0.00122
299 HEART VALVE DEVELOPMENT 3 34 7.839e-05 0.00122
300 REGULATION OF DNA BINDING 4 93 7.909e-05 0.001227
301 REGULATION OF DNA BIOSYNTHETIC PROCESS 4 94 8.245e-05 0.001275
302 RHYTHMIC PROCESS 6 298 8.491e-05 0.001308
303 RESPONSE TO MINERALOCORTICOID 3 35 8.56e-05 0.001312
304 CELLULAR RESPONSE TO OXIDATIVE STRESS 5 184 8.573e-05 0.001312
305 POSITIVE REGULATION OF DNA METABOLIC PROCESS 5 185 8.795e-05 0.001337
306 CELL JUNCTION ORGANIZATION 5 185 8.795e-05 0.001337
307 MULTICELLULAR ORGANISM REPRODUCTION 9 768 8.956e-05 0.001357
308 REGULATION OF CELLULAR COMPONENT MOVEMENT 9 771 9.226e-05 0.001394
309 HEAD MORPHOGENESIS 3 36 9.322e-05 0.001404
310 MESENCHYME DEVELOPMENT 5 190 9.972e-05 0.001492
311 STEM CELL DIFFERENTIATION 5 190 9.972e-05 0.001492
312 RESPONSE TO NERVE GROWTH FACTOR 3 37 0.0001013 0.00151
313 IN UTERO EMBRYONIC DEVELOPMENT 6 311 0.0001073 0.001591
314 DEVELOPMENTAL MATURATION 5 193 0.0001073 0.001591
315 PEPTIDYL LYSINE MODIFICATION 6 312 0.0001092 0.001614
316 MESENCHYME MORPHOGENESIS 3 38 0.0001098 0.001616
317 CELLULAR RESPONSE TO REACTIVE OXYGEN SPECIES 4 104 0.0001221 0.001792
318 RESPONSE TO CADMIUM ION 3 40 0.0001281 0.001874
319 TUBE MORPHOGENESIS 6 323 0.000132 0.001925
320 NEGATIVE REGULATION OF CATABOLIC PROCESS 5 203 0.000136 0.001978
321 REGULATION OF DNA DEPENDENT DNA REPLICATION 3 41 0.000138 0.001994
322 NEGATIVE REGULATION OF FAT CELL DIFFERENTIATION 3 41 0.000138 0.001994
323 EYE DEVELOPMENT 6 326 0.0001388 0.002
324 POSITIVE REGULATION OF CELL DEVELOPMENT 7 472 0.0001421 0.002041
325 REGULATION OF LEUKOCYTE PROLIFERATION 5 206 0.0001457 0.002086
326 REGULATION OF CATION TRANSMEMBRANE TRANSPORT 5 208 0.0001524 0.002176
327 REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 10 1021 0.0001532 0.00218
328 RESPONSE TO INORGANIC SUBSTANCE 7 479 0.0001557 0.002204
329 LYMPHOCYTE DIFFERENTIATION 5 209 0.0001559 0.002204
330 DNA REPAIR 7 480 0.0001577 0.002223
331 POSITIVE REGULATION OF PROTEIN SECRETION 5 211 0.000163 0.002284
332 NEGATIVE REGULATION OF CYTOKINE PRODUCTION 5 211 0.000163 0.002284
333 REGULATION OF RESPONSE TO STRESS 12 1468 0.0001682 0.00235
334 BODY MORPHOGENESIS 3 44 0.0001705 0.002376
335 EXOCRINE SYSTEM DEVELOPMENT 3 45 0.0001824 0.002534
336 REGULATION OF MITOCHONDRION ORGANIZATION 5 218 0.0001897 0.002619
337 CELLULAR RESPONSE TO STEROID HORMONE STIMULUS 5 218 0.0001897 0.002619
338 EPITHELIAL CELL DIFFERENTIATION 7 495 0.0001905 0.002622
339 RESPONSE TO ANTIBIOTIC 3 47 0.0002077 0.002843
340 POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS 3 47 0.0002077 0.002843
341 RESPONSE TO NITROGEN COMPOUND 9 859 0.0002086 0.002846
342 RESPONSE TO OXIDATIVE STRESS 6 352 0.0002104 0.002862
343 REGULATION OF B CELL ACTIVATION 4 121 0.0002188 0.002969
344 REGULATION OF LIPID KINASE ACTIVITY 3 48 0.0002212 0.002992
345 CELL FATE COMMITMENT 5 227 0.0002288 0.003086
346 CENTRAL NERVOUS SYSTEM DEVELOPMENT 9 872 0.0002333 0.003137
347 NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 8 684 0.0002343 0.003142
348 LYMPHOCYTE HOMEOSTASIS 3 50 0.0002498 0.003302
349 KIDNEY EPITHELIUM DEVELOPMENT 4 125 0.0002479 0.003302
350 FACE DEVELOPMENT 3 50 0.0002498 0.003302
351 RESPONSE TO PROGESTERONE 3 50 0.0002498 0.003302
352 RESPONSE TO GAMMA RADIATION 3 50 0.0002498 0.003302
353 POSITIVE REGULATION OF BINDING 4 127 0.0002634 0.003471
354 CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION 6 368 0.0002672 0.003512
355 POSITIVE REGULATION OF SECRETION 6 370 0.0002751 0.003605
356 NEGATIVE REGULATION OF T CELL PROLIFERATION 3 52 0.0002807 0.003669
357 REGULATION OF LIGASE ACTIVITY 4 130 0.0002879 0.003752
358 REGULATION OF HYDROLASE ACTIVITY 11 1327 0.0002947 0.003821
359 CELL MATURATION 4 131 0.0002964 0.003821
360 PROTEIN STABILIZATION 4 131 0.0002964 0.003821
361 CELLULAR COMPONENT MORPHOGENESIS 9 900 0.0002949 0.003821
362 TISSUE MORPHOGENESIS 7 533 0.0002988 0.003841
363 CELL PROJECTION ORGANIZATION 9 902 0.0002997 0.003842
364 RESPONSE TO TOXIC SUBSTANCE 5 241 0.0003016 0.003856
365 ENDOCARDIUM DEVELOPMENT 2 11 0.0003189 0.004032
366 REGULATION OF EXTRACELLULAR MATRIX ASSEMBLY 2 11 0.0003189 0.004032
367 NEGATIVE REGULATION OF CELLULAR SENESCENCE 2 11 0.0003189 0.004032
368 NEGATIVE REGULATION OF INTERLEUKIN 17 PRODUCTION 2 11 0.0003189 0.004032
369 EMBRYONIC MORPHOGENESIS 7 539 0.0003198 0.004032
370 MESENCHYMAL CELL DIFFERENTIATION 4 134 0.0003231 0.004064
371 RESPONSE TO EXTERNAL STIMULUS 13 1821 0.0003262 0.004091
372 EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY 3 55 0.0003315 0.004124
373 CRANIAL SKELETAL SYSTEM DEVELOPMENT 3 55 0.0003315 0.004124
374 REGULATION OF B CELL PROLIFERATION 3 55 0.0003315 0.004124
375 CELL GROWTH 4 135 0.0003324 0.004125
376 RESPONSE TO ETHANOL 4 136 0.0003419 0.004208
377 NEGATIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY 4 136 0.0003419 0.004208
378 GLIAL CELL DIFFERENTIATION 4 136 0.0003419 0.004208
379 EPITHELIAL TO MESENCHYMAL TRANSITION 3 56 0.0003497 0.004293
380 REGULATION OF PROTEIN SECRETION 6 389 0.0003594 0.004401
381 NEGATIVE REGULATION OF CELL CELL ADHESION 4 138 0.0003614 0.004413
382 REGULATION OF CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE 3 57 0.0003684 0.004485
383 CELLULAR RESPONSE TO HORMONE STIMULUS 7 552 0.0003692 0.004485
384 REGULATION OF NEURON DEATH 5 252 0.0003702 0.004486
385 NEGATIVE REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL 4 139 0.0003714 0.004489
386 REGULATION OF PEPTIDASE ACTIVITY 6 392 0.0003744 0.004513
387 MITOTIC SISTER CHROMATID COHESION 2 12 0.0003821 0.004594
388 CELLULAR RESPONSE TO CORTICOSTEROID STIMULUS 3 58 0.0003879 0.004651
389 LEUKOCYTE CELL CELL ADHESION 5 255 0.0003908 0.004675
390 NEGATIVE REGULATION OF HYDROLASE ACTIVITY 6 397 0.0004004 0.004778
391 NEGATIVE REGULATION OF CELL DIVISION 3 60 0.0004287 0.005075
392 NEURON PROJECTION MORPHOGENESIS 6 402 0.0004279 0.005075
393 LEUKOCYTE HOMEOSTASIS 3 60 0.0004287 0.005075
394 REGULATION OF RESPONSE TO DNA DAMAGE STIMULUS 4 145 0.0004359 0.005148
395 MEMBRANE DEPOLARIZATION 3 61 0.0004501 0.005245
396 POSITIVE REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 2 13 0.0004508 0.005245
397 RESPONSE TO ESTRADIOL 4 146 0.0004474 0.005245
398 CELLULAR RESPONSE TO HYDROGEN PEROXIDE 3 61 0.0004501 0.005245
399 REGULATION OF HISTONE PHOSPHORYLATION 2 13 0.0004508 0.005245
400 EMBRYONIC ORGAN DEVELOPMENT 6 406 0.0004509 0.005245
401 REGULATION OF CARTILAGE DEVELOPMENT 3 63 0.0004949 0.005734
402 CHROMATIN REMODELING 4 150 0.0004954 0.005734
403 NEGATIVE REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS 3 64 0.0005184 0.005953
404 POSITIVE REGULATION OF HISTONE DEACETYLATION 2 14 0.0005251 0.005953
405 REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS 4 152 0.0005208 0.005953
406 DETERMINATION OF ADULT LIFESPAN 2 14 0.0005251 0.005953
407 CRANIOFACIAL SUTURE MORPHOGENESIS 2 14 0.0005251 0.005953
408 REGULATION OF EXTRACELLULAR MATRIX DISASSEMBLY 2 14 0.0005251 0.005953
409 POSITIVE REGULATION OF RESPONSE TO DNA DAMAGE STIMULUS 3 64 0.0005184 0.005953
410 PATTERN SPECIFICATION PROCESS 6 418 0.0005258 0.005953
411 RESPONSE TO LAMINAR FLUID SHEAR STRESS 2 14 0.0005251 0.005953
412 REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS 5 274 0.0005422 0.006123
413 POSITIVE REGULATION OF PEPTIDASE ACTIVITY 4 154 0.0005471 0.006164
414 NEGATIVE REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS 3 66 0.0005674 0.006346
415 NEGATIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY 3 66 0.0005674 0.006346
416 LENS DEVELOPMENT IN CAMERA TYPE EYE 3 66 0.0005674 0.006346
417 GAMETE GENERATION 7 595 0.000578 0.006449
418 REGULATION OF SISTER CHROMATID SEGREGATION 3 67 0.0005929 0.0066
419 REGULATION OF HAIR FOLLICLE DEVELOPMENT 2 15 0.000605 0.006639
420 NEGATIVE REGULATION OF B CELL PROLIFERATION 2 15 0.000605 0.006639
421 REGULATION OF DEPHOSPHORYLATION 4 158 0.0006024 0.006639
422 NEGATIVE REGULATION OF CELL ACTIVATION 4 158 0.0006024 0.006639
423 POSITIVE REGULATION OF T CELL APOPTOTIC PROCESS 2 15 0.000605 0.006639
424 RESPONSE TO LIGHT STIMULUS 5 280 0.0005981 0.006639
425 DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION 7 602 0.0006195 0.006766
426 POSITIVE REGULATION OF CELL CYCLE PHASE TRANSITION 3 68 0.0006192 0.006766
427 REGENERATION 4 161 0.0006465 0.007028
428 NEGATIVE REGULATION OF OSSIFICATION 3 69 0.0006463 0.007028
429 POSITIVE REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION 4 162 0.0006617 0.007177
430 NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 6 437 0.000664 0.007185
431 NEGATIVE REGULATION OF DNA DEPENDENT DNA REPLICATION 2 16 0.0006903 0.007418
432 CELLULAR RESPONSE TO ANTIBIOTIC 2 16 0.0006903 0.007418
433 ATRIOVENTRICULAR VALVE MORPHOGENESIS 2 16 0.0006903 0.007418
434 ENDODERM DEVELOPMENT 3 71 0.0007026 0.007533
435 PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS 13 1977 0.0007204 0.007706
436 LEUKOCYTE DIFFERENTIATION 5 292 0.0007227 0.007713
437 POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION 4 167 0.0007414 0.007894
438 IMMUNE SYSTEM PROCESS 13 1984 0.000745 0.007914
439 REGULATION OF HOMEOSTATIC PROCESS 6 447 0.0007472 0.007919
440 BRANCH ELONGATION OF AN EPITHELIUM 2 17 0.0007811 0.008223
441 NEGATIVE REGULATION OF CELL AGING 2 17 0.0007811 0.008223
442 POSITIVE REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 2 17 0.0007811 0.008223
443 UROGENITAL SYSTEM DEVELOPMENT 5 299 0.0008039 0.008425
444 REGULATION OF CELL ADHESION 7 629 0.0008023 0.008425
445 SKELETAL SYSTEM DEVELOPMENT 6 455 0.0008194 0.008567
446 REGULATION OF CELLULAR RESPONSE TO HEAT 3 76 0.0008568 0.008939
447 POSITIVE REGULATION OF PROTEIN DEACETYLATION 2 18 0.0008774 0.009113
448 UTERUS DEVELOPMENT 2 18 0.0008774 0.009113
449 HOMEOSTASIS OF NUMBER OF CELLS 4 175 0.0008828 0.009148
450 CELLULAR TRANSITION METAL ION HOMEOSTASIS 3 77 0.00089 0.009203
451 MITOCHONDRIAL TRANSPORT 4 177 0.0009209 0.009501
452 HEART DEVELOPMENT 6 466 0.0009274 0.009547
453 REGULATION OF MICROTUBULE POLYMERIZATION OR DEPOLYMERIZATION 4 178 0.0009403 0.009659
454 REGULATION OF LEUKOCYTE APOPTOTIC PROCESS 3 79 0.0009588 0.009805
455 ERBB SIGNALING PATHWAY 3 79 0.0009588 0.009805
456 PROTEIN COMPLEX SUBUNIT ORGANIZATION 11 1527 0.0009641 0.009838
457 POSITIVE REGULATION OF MAPK CASCADE 6 470 0.0009693 0.009869
458 REGULATION OF ACTIN FILAMENT BASED PROCESS 5 312 0.0009726 0.009881
459 ATRIOVENTRICULAR VALVE DEVELOPMENT 2 19 0.0009791 0.009926
NumGOOverlapSizeP ValueAdj. P Value
1 PROTEIN COMPLEX BINDING 18 935 2.838e-12 2.636e-09
2 KINASE BINDING 15 606 8.528e-12 3.961e-09
3 ENZYME BINDING 22 1737 1.965e-11 6.086e-09
4 MACROMOLECULAR COMPLEX BINDING 20 1399 2.737e-11 6.356e-09
5 CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY 5 12 5.594e-11 8.818e-09
6 CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE REGULATOR ACTIVITY 6 28 5.695e-11 8.818e-09
7 PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY 6 30 8.943e-11 1.187e-08
8 KINASE REGULATOR ACTIVITY 9 186 6.391e-10 7.422e-08
9 PROTEIN KINASE ACTIVITY 12 640 3.247e-08 3.352e-06
10 CORE PROMOTER BINDING 7 152 8.381e-08 6.488e-06
11 KINASE INHIBITOR ACTIVITY 6 89 7.849e-08 6.488e-06
12 KINASE ACTIVITY 13 842 7.657e-08 6.488e-06
13 RNA POLYMERASE II TRANSCRIPTION FACTOR BINDING 6 104 1.994e-07 1.425e-05
14 TRANSCRIPTION FACTOR BINDING 10 524 4.59e-07 3.046e-05
15 TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS 13 992 5.046e-07 3.125e-05
16 CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 4 34 1.397e-06 8.11e-05
17 PROTEIN HETERODIMERIZATION ACTIVITY 9 468 1.743e-06 9.526e-05
18 MOLECULAR FUNCTION REGULATOR 14 1353 2.813e-06 0.0001452
19 TRANSFORMING GROWTH FACTOR BETA RECEPTOR BINDING 4 50 6.739e-06 0.0003295
20 PROTEIN SERINE THREONINE KINASE ACTIVITY 8 445 1.143e-05 0.0005309
21 CYCLIN BINDING 3 19 1.303e-05 0.0005763
22 PROTEIN DIMERIZATION ACTIVITY 12 1149 1.553e-05 0.00064
23 ENZYME REGULATOR ACTIVITY 11 959 1.585e-05 0.00064
24 REGULATORY REGION NUCLEIC ACID BINDING 10 818 2.391e-05 0.0009254
25 SMAD BINDING 4 72 2.894e-05 0.001075
26 CHAPERONE BINDING 4 81 4.605e-05 0.001645
27 NF KAPPAB BINDING 3 30 5.356e-05 0.001843
28 RECEPTOR SIGNALING PROTEIN ACTIVITY 5 172 6.231e-05 0.002067
29 CHROMATIN BINDING 7 435 8.563e-05 0.002743
30 RNA POLYMERASE II ACTIVATING TRANSCRIPTION FACTOR BINDING 3 36 9.322e-05 0.002887
31 ENZYME INHIBITOR ACTIVITY 6 378 0.0003084 0.009243
NumGOOverlapSizeP ValueAdj. P Value
1 PROTEIN KINASE COMPLEX 9 90 8.901e-13 2.599e-10
2 CYCLIN DEPENDENT PROTEIN KINASE HOLOENZYME COMPLEX 7 31 8.519e-13 2.599e-10
3 TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS 10 237 2.476e-10 4.82e-08
4 TRANSFERASE COMPLEX 14 703 8.349e-10 1.219e-07
5 CHROMOSOME 15 880 1.545e-09 1.805e-07
6 CHROMATIN 11 441 7.252e-09 7.058e-07
7 CATALYTIC COMPLEX 14 1038 1.157e-07 9.65e-06
8 TRANSCRIPTION FACTOR COMPLEX 8 298 5.869e-07 4.285e-05
9 MICROTUBULE CYTOSKELETON 11 1068 4.28e-05 0.002777
10 RNA POLYMERASE II TRANSCRIPTION FACTOR COMPLEX 4 101 0.000109 0.006367
11 CHROMOSOMAL REGION 6 330 0.0001483 0.007875

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 Cell_cycle_hsa04110 35 124 1.738e-68 9.039e-67
2 Cellular_senescence_hsa04218 20 160 7.851e-30 2.041e-28
3 FoxO_signaling_pathway_hsa04068 15 132 1.129e-21 1.957e-20
4 p53_signaling_pathway_hsa04115 11 68 7.903e-18 1.027e-16
5 Hippo_signaling_pathway_hsa04390 12 154 2.031e-15 2.112e-14
6 TGF_beta_signaling_pathway_hsa04350 8 84 2.699e-11 2.339e-10
7 PI3K_Akt_signaling_pathway_hsa04151 12 352 3.769e-11 2.8e-10
8 Wnt_signaling_pathway_hsa04310 9 146 7.357e-11 4.782e-10
9 MAPK_signaling_pathway_hsa04010 8 295 5.438e-07 2.94e-06
10 Oocyte_meiosis_hsa04114 6 124 5.654e-07 2.94e-06
11 Jak_STAT_signaling_pathway_hsa04630 6 162 2.699e-06 1.276e-05
12 Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 5 139 2.25e-05 9.749e-05
13 ErbB_signaling_pathway_hsa04012 4 85 5.564e-05 0.0002226
14 Adherens_junction_hsa04520 3 72 0.0007319 0.002718
15 HIF_1_signaling_pathway_hsa04066 3 100 0.001891 0.006556
16 AMPK_signaling_pathway_hsa04152 3 121 0.003249 0.01056
17 Cytokine_cytokine_receptor_interaction_hsa04060 4 270 0.004273 0.01221
18 Ferroptosis_hsa04216 2 40 0.004322 0.01221
19 Apelin_signaling_pathway_hsa04371 3 137 0.004602 0.01221
20 Apoptosis_hsa04210 3 138 0.004697 0.01221
21 Hedgehog_signaling_pathway_hsa04340 2 47 0.005925 0.01459
22 Notch_signaling_pathway_hsa04330 2 48 0.006173 0.01459
23 Mitophagy_animal_hsa04137 2 65 0.01109 0.02506
24 Focal_adhesion_hsa04510 3 199 0.01278 0.02769

lncRNA-mediated sponge

(Download full result)

Num lncRNA miRNAs           miRNAs count     Gene Sponge regulatory network lncRNA log2FC lncRNA pvalue Gene log2FC Gene pvalue lncRNA-gene Pearson correlation
1

RP11-166D19.1

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-335-5p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p;hsa-miR-96-5p 18 CCND2 Sponge network -3.855 0 -2.427 0 0.629
2

MAGI2-AS3

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-335-5p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p 16 CCND2 Sponge network -2.414 0 -2.427 0 0.545
3

MIR143HG

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-335-5p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p 17 CCND2 Sponge network -4.237 0 -2.427 0 0.544
4 RP11-284N8.3 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-96-5p 14 CCND2 Sponge network -1.414 0.007 -2.427 0 0.514
5

C20orf166-AS1

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p 13 CCND2 Sponge network -6.333 0 -2.427 0 0.513
6

LINC00702

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-877-5p;hsa-miR-96-5p 16 CCND2 Sponge network -2.704 0 -2.427 0 0.509
7

HAND2-AS1

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-423-5p 14 CCND2 Sponge network -5.605 0 -2.427 0 0.497
8

RP11-175K6.1

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-96-5p 13 CCND2 Sponge network -2.386 0 -2.427 0 0.477
9 RP11-325F22.2 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-877-5p;hsa-miR-96-5p 12 CCND2 Sponge network -1.801 0.01297 -2.427 0 0.466
10

GAS6-AS2

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p 12 CCND2 Sponge network -2.655 0 -2.427 0 0.458
11

VIM-AS1

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a 10 CCND2 Sponge network -1.424 0.00627 -2.427 0 0.455
12 LINC00861 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-378a-3p;hsa-miR-877-5p;hsa-miR-96-5p 12 CCND2 Sponge network -1.254 0.02528 -2.427 0 0.446
13 AC093627.8 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-324-3p 10 CCND2 Sponge network -5.744 0 -2.427 0 0.445
14

ADAMTS9-AS1

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-335-5p;hsa-miR-877-5p;hsa-miR-96-5p 15 CCND2 Sponge network -7.614 0 -2.427 0 0.443
15

DNM3OS

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-378a-3p;hsa-miR-96-5p 14 CCND2 Sponge network -2.298 1.0E-5 -2.427 0 0.44
16

RP11-867G23.10

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-378a-3p;hsa-miR-423-5p 11 CCND2 Sponge network -5.684 0 -2.427 0 0.437
17 AP001055.6 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-423-5p 11 CCND2 Sponge network -1.091 0.00522 -2.427 0 0.434
18

RP11-426C22.5

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-423-5p 13 CCND2 Sponge network -0.559 0.08048 -2.427 0 0.425
19 PCED1B-AS1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-877-5p;hsa-miR-96-5p 11 CCND2 Sponge network -0.575 0.17488 -2.427 0 0.418
20 LINC00092 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-423-5p 11 CCND2 Sponge network -3.407 1.0E-5 -2.427 0 0.417
21 C4A-AS1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-423-5p;hsa-miR-877-5p;hsa-miR-96-5p 13 CCND2 Sponge network -1.76 0.00265 -2.427 0 0.416
22 AC011526.1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-320a;hsa-miR-96-5p 10 CCND2 Sponge network -1.209 1.0E-5 -2.427 0 0.413
23

BZRAP1-AS1

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-335-5p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p 16 CCND2 Sponge network -2.343 0 -2.427 0 0.412
24

NR2F1-AS1

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p 16 CCND2 Sponge network -1.881 0 -2.427 0 0.411
25 LINC00996 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-335-5p 11 CCND2 Sponge network -1.208 0.03775 -2.427 0 0.406
26

RP11-753H16.3

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-320a;hsa-miR-335-5p 10 CCND2 Sponge network -5.702 0 -2.427 0 0.402
27 RP11-20J15.3 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-877-5p 12 CCND2 Sponge network -5.104 8.0E-5 -2.427 0 0.394
28

NR2F1-AS1

hsa-miR-103a-3p;hsa-miR-107;hsa-miR-141-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-191-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-34a-5p;hsa-miR-501-3p 11 CDK6 Sponge network -1.881 0 -0.774 0.06479 0.393
29

TBX5-AS1

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-877-5p 14 CCND2 Sponge network -2.557 2.0E-5 -2.427 0 0.387
30 RP11-554A11.4 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-423-5p 11 CCND2 Sponge network -3.989 0 -2.427 0 0.379
31 RP11-693J15.4 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a 12 CCND2 Sponge network -3.319 0.00281 -2.427 0 0.375
32

AC020571.3

hsa-let-7a-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-877-5p;hsa-miR-96-5p 11 CCND2 Sponge network -0.862 0.18422 -2.427 0 0.371
33 RP11-180N14.1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-96-5p 12 CCND2 Sponge network -4.46 0 -2.427 0 0.371
34

MEG3

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-96-5p 16 CCND2 Sponge network -2.367 0 -2.427 0 0.37
35 RP11-426C22.4 hsa-let-7a-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p 10 CCND2 Sponge network -0.045 0.93351 -2.427 0 0.367
36

LINC00883

hsa-miR-103a-3p;hsa-miR-107;hsa-miR-141-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-191-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-34a-5p;hsa-miR-501-3p 10 CDK6 Sponge network -0.614 0.0511 -0.774 0.06479 0.364
37

LINC00702

hsa-miR-103a-3p;hsa-miR-107;hsa-miR-141-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-191-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-34a-5p;hsa-miR-501-3p 11 CDK6 Sponge network -2.704 0 -0.774 0.06479 0.364
38

AF131217.1

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-335-5p;hsa-miR-423-5p;hsa-miR-877-5p;hsa-miR-96-5p 15 CCND2 Sponge network -5.31 0 -2.427 0 0.363
39 RP4-647J21.1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-378a-3p;hsa-miR-423-5p 11 CCND2 Sponge network -0.501 0.33476 -2.427 0 0.362
40 RP11-367G6.3 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-877-5p 10 CCND2 Sponge network -1.318 0.14472 -2.427 0 0.36
41 RP1-151F17.2 hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-335-5p;hsa-miR-877-5p;hsa-miR-96-5p 10 CCND2 Sponge network -1.606 0 -2.427 0 0.36
42

RP11-356J5.12

hsa-miR-103a-3p;hsa-miR-107;hsa-miR-141-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-191-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-501-3p 10 CDK6 Sponge network -2.015 0 -0.774 0.06479 0.358
43 RP11-81H14.2 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-96-5p 13 CCND2 Sponge network -2.322 0.00014 -2.427 0 0.353
44

PDZRN3-AS1

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a 12 CCND2 Sponge network -5.049 1.0E-5 -2.427 0 0.353
45

RP11-887P2.5

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p 10 CCND2 Sponge network -6.751 0 -2.427 0 0.352
46

FENDRR

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-423-5p;hsa-miR-96-5p 15 CCND2 Sponge network -4.793 0 -2.427 0 0.35
47

ACTA2-AS1

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-96-5p 14 CCND2 Sponge network -3.838 0 -2.427 0 0.348
48 RP11-161M6.2 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-423-5p;hsa-miR-96-5p 13 CCND2 Sponge network -1.332 0.00015 -2.427 0 0.346
49 AC010226.4 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-96-5p 10 CCND2 Sponge network -1.506 0 -2.427 0 0.344
50 LINC00565 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p 11 CCND2 Sponge network -1.493 0.05998 -2.427 0 0.342
51

MIR497HG

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p;hsa-miR-96-5p 16 CCND2 Sponge network -3.802 0 -2.427 0 0.341
52

LINC00473

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-423-5p;hsa-miR-877-5p 13 CCND2 Sponge network -5.53 0 -2.427 0 0.337
53 CTC-378H22.2 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-324-3p;hsa-miR-423-5p;hsa-miR-877-5p 11 CCND2 Sponge network -1.776 0.01283 -2.427 0 0.337
54 RP11-1024P17.1 hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a 10 CCND2 Sponge network -1.552 0 -2.427 0 0.336
55

LINC00163

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p 10 CCND2 Sponge network -4.312 0.00014 -2.427 0 0.333
56

RP11-326C3.11

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-877-5p 12 CCND2 Sponge network -1.196 3.0E-5 -2.427 0 0.324
57

AC002480.3

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-378a-3p;hsa-miR-423-5p 12 CCND2 Sponge network -1.522 0.03484 -2.427 0 0.322
58

TP73-AS1

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-96-5p 16 CCND2 Sponge network -1.97 0 -2.427 0 0.321
59

RP11-456K23.1

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-877-5p 13 CCND2 Sponge network -1.962 1.0E-5 -2.427 0 0.317
60 AC002480.5 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-378a-3p 10 CCND2 Sponge network -2.128 0.02032 -2.427 0 0.312
61

RP11-805I24.3

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p 13 CCND2 Sponge network -5.815 0 -2.427 0 0.312
62

RP11-356J5.12

hsa-let-7a-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-335-5p;hsa-miR-423-5p 14 CCND2 Sponge network -2.015 0 -2.427 0 0.31
63

LINC00327

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-96-5p 11 CCND2 Sponge network -1.951 0.01135 -2.427 0 0.306
64

BVES-AS1

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-320a;hsa-miR-378a-3p;hsa-miR-877-5p 10 CCND2 Sponge network -4.161 1.0E-5 -2.427 0 0.303
65

RP11-401P9.4

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-877-5p 13 CCND2 Sponge network -2.738 0 -2.427 0 0.299
66 RP11-403B2.7 hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-423-5p 10 CCND2 Sponge network -2.507 0.00687 -2.427 0 0.299
67 RP11-25K19.1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p 10 CCND2 Sponge network -1.478 0.00829 -2.427 0 0.298
68 RP11-1008C21.2 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p 10 CCND2 Sponge network -0.999 0.0012 -2.427 0 0.294
69

LINC00883

hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-423-5p 11 CCND2 Sponge network -0.614 0.0511 -2.427 0 0.286
70 GATA6-AS1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p 12 CCND2 Sponge network -3.855 0 -2.427 0 0.282
71 MIR22HG hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-877-5p 11 CCND2 Sponge network -1.994 0 -2.427 0 0.281
72 CTD-2013N24.2 hsa-let-7a-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p 11 CCND2 Sponge network -1.002 1.0E-5 -2.427 0 0.279
73 DIO3OS hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p 15 CCND2 Sponge network -3.619 0 -2.427 0 0.278
74 RP11-359E10.1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-423-5p 11 CCND2 Sponge network -1.216 0.0438 -2.427 0 0.276
75 RP11-13K12.5 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-423-5p;hsa-miR-877-5p 12 CCND2 Sponge network -4.086 0 -2.427 0 0.275
76 MEG9 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-378a-3p 11 CCND2 Sponge network -3.37 3.0E-5 -2.427 0 0.273
77

RP11-536K7.3

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-877-5p 10 CCND2 Sponge network -0.673 0.17143 -2.427 0 0.272
78 RP11-389G6.3 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-378a-3p;hsa-miR-423-5p 14 CCND2 Sponge network -7.573 0 -2.427 0 0.272
79 RP4-639F20.1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-96-5p 12 CCND2 Sponge network -1.492 1.0E-5 -2.427 0 0.269
80 AC016747.3 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p 12 CCND2 Sponge network 0.026 0.94846 -2.427 0 0.267
81 HCG22 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-423-5p;hsa-miR-96-5p 12 CCND2 Sponge network -2.084 0.04175 -2.427 0 0.262
82 CTD-2554C21.3 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p 12 CCND2 Sponge network -2.359 0.00283 -2.427 0 0.257
83

LINC00982

hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-423-5p 13 CCND2 Sponge network -3.353 3.0E-5 -2.427 0 0.254
84

FLG-AS1

hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-335-5p;hsa-miR-378a-3p;hsa-miR-877-5p 14 CCND2 Sponge network -1.812 0.00363 -2.427 0 0.253
85 RASSF8-AS1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-182-5p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-378a-3p 10 CCND2 Sponge network -0.877 0.00508 -2.427 0 0.253

Quest ID: 0c186a183b749fef68527ac36ad4f532